HomeInsightsPE

SMS Pharmaceuticals Ltd P/E Ratio

SMS Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 0.3 Cr

Volume transacted

stocks purchased

11.4 K

stocks traded

Last Updated time: 22 Jul 9.00 AM

Image

SMS Pharmaceuticals Ltd

NSE: SMSPHARMA

PE

40.3

Last updated : 22 Jul 9.00 AM

Key Highlights

    The P/E Ratio of SMS Pharmaceuticals Ltd is 40.3 as of 22 Jul 9.00 AM .a1#The P/E Ratio of SMS Pharmaceuticals Ltd changed from 13.2 on March 2019 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years. a1#The Latest Trading Price of SMS Pharmaceuticals Ltd is ₹ 237.3 as of 19 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.6 in 5 years. This represents a CAGR of -0.64%a1# The PE Ratio of Automobile industry is 18.5. The PE Ratio of Finance industry is 23.8. The PE Ratio of IT - Software industry is 29.3. The PE Ratio of Pharmaceuticals industry is 38.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 20.4. In 2024a1#The Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 526.96 crore on March 2019 to ₹ 489.29 crore on March 2023 . This represents a CAGR of -1.47% over 5 years. a1#The Revenue of SMS Pharmaceuticals Ltd changed from ₹ 65.19 crore to ₹ 247.44 crore over 8 quarters. This represents a CAGR of 94.82% a1#The EBITDA of SMS Pharmaceuticals Ltd changed from ₹ -0.01 crore to ₹ 35.26 crore over 8 quarters. This represents a CAGR of NaN% a1#The Net Pr of SMS Pharmaceuticals Ltd changed from ₹ -10.19 crore to ₹ 16.05 crore over 8 quarters. This represents a CAGR of NaN% a1#The Dividend Payout of SMS Pharmaceuticals Ltd changed from 5.11 % on March 2019 to 62.28 % on March 2023 . This represents a CAGR of 64.89% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of SMS Pharmaceuticals Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of SMS Pharmaceuticals Ltd

Period
Mar '1913.2
Mar '207.1
Mar '2116.8
Mar '2212.8
Mar '230

Company Fundamentals for SMS Pharmaceuticals Ltd

Market Cap

2,008 Cr

EPS

5.9

P/E Ratio (TTM) *

40.3

P/B Ratio (TTM) *

3.8

Day’s High

244.3

Day’s Low

233.45

DTE *

0.5

ROE *

9.3

52 Week High

265.0

52 Week Low

105.0

ROCE *

11.0

* All values are consolidated

Last Updated time: 22 Jul 9.00 AM

* All values are consolidated

Last Updated time: 22 Jul 9.00 AM

Image

SMS Pharmaceuticals Ltd

NSE: SMSPHARMA

PRICE

237.3

-3.00 (-1.25%)

stock direction

Last updated : 19 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of SMS Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

2

T

Asset Value vs Market Value of SMS Pharmaceuticals Ltd

Market Value

2,009

Asset Value

414

3.9 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
SMS Pharmaceuticals Ltd402,008
Sun Pharmaceuticals Industries Ltd37376,324
Divis Laboratories Ltd74119,994
Cipla Ltd28119,929
Zydus Lifesciences Ltd29115,174
Dr Reddys Laboratories Ltd20110,759

Key Valuation Metric of SMS Pharmaceuticals Ltd

Earnings

49 Cr

40.3 X

PE Ratio

Market Cap

₹2008Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

49 Cr

40.3 X

PE Ratio

Market Cap

₹2008Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of SMS Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of SMS Pharmaceuticals Ltd

Period
Mar '19527
Mar '20226
Mar '211053
Mar '22794
Mar '23489

* All values are a in crore

×

Historical Revenue of SMS Pharmaceuticals Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of SMS Pharmaceuticals Ltd

Period
Jun '2265
Sep '22160
Dec '22151
Mar '23151
Jun '23136
Sep '23167
Dec '23163
Mar '24247

* All values are a in crore

×

Historical EBITDA of SMS Pharmaceuticals Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of SMS Pharmaceuticals Ltd

Period
Jun '220
Sep '2214
Dec '2221
Mar '2324
Jun '2327
Sep '2329
Dec '2330
Mar '2435

* All values are a in crore

×

Historical Net Profit of SMS Pharmaceuticals Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of SMS Pharmaceuticals Ltd

Period
Jun '22-10
Sep '221
Dec '225
Mar '238
Jun '239
Sep '2312
Dec '2312
Mar '2416

* All values are a in crore

×

Historical Dividend Payout of SMS Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of SMS Pharmaceuticals Ltd

Period
Mar '195
Mar '206
Mar '214
Mar '224
Mar '2362

* All values are a in %

About SMS Pharmaceuticals Ltd

About SMS Pharmaceuticals Ltd

    SMS Pharmaceuticals Limited is a Public company incorporated in December 14, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa in Vijayanagaram Dist. Its business activity is a single primary business segment of 'Bulk Drugs'. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries. During the year 2015-16, the Company had sub divided the face value of share of Rs 10/- each into face value of Rs 1/- of each with record date of 18th December 2015. During FY 2015-16, the Board has approved the 'Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit - I, IV & V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), with an object to reduce the impact of Semi Regulated Units on Regulated Units, achieving operational efficiencies, site synergies and streamlining its current structure. The Draft Scheme of Arrangement is subject to the Approvals of Stock Exchanges, Securities Board of India Limited, Reserve Bank of India and other regulatory authorities and also Hon'ble High Court of Judicature at Hyderabad for the State of Telangana and Andhra Pradesh. During FY 2016-17, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2016-17, the Company had acquired 5,11,400 equity shares of face value of Rs 10/- each in the said associate at an average price of Rs 157.21. Further, the Company had also made an investment in 1000 equity shares of Sireen Drugs Private Limited of Rs 10/- each. SMS Lifesciences India Limited is the wholly owned subsidiary of the Company during the Financial Year 2016-17. In FY 2017-18, the Scheme of arrangement between SMS Pharmaceuticals Limited (Demerged Company) with SMS Lifesciences India Limited (Resulting Company) and their respective Shareholders and Creditors provides for the demerger of the Semi Regulated Units No. I, IV and V along with premises situated at Industrial Estate, Santhnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad ; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units (Demerged Undertaking) of SMS Pharmaceuticals Limited, the 'Demerged Company' into SMS Lifesciences India Limited, the 'Resulting Company as specified in the scheme. The scheme was approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide its Order No. C.P (CAA) No.7/230/232/HDB/2017 dated 15th May 2017. The effective date of the Scheme is 17th May 2017. SMS Lifesciences India Limited (Resulting Company) in accordance with the approved Scheme of Arrangement has allotted 30,23,287 equity shares of Rs.10/- each to the shareholders of the company by fixing Record Date as on 23rd June, 2017. Pursuant to approved Scheme, the Resulting Company shares will be listed on Stock Exchanges viz., BSE & NSE where the equity shares of SMS Pharmaceuticals Limited are listed. The Company had made investment in its associate company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2017-18, the Company had acquired 7,84,100 equity shares of face value of Rs.10/- each in the said associate at an average price of Rs.200.81. During FY 2018-19, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. The Company held 38,50,165 equity shares of Rs 10/- each in VKT Pharma Private Limited as on 31st March 2019 as investments.

SMS Pharmaceuticals Ltd News Hub

News

Board of SMS Pharmaceuticals recommends final dividend

SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting he...

Read more

29 May 202416:05

News

SMS Pharmaceuticals to conduct board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May...

Read more

28 May 202413:41

News

SMS Pharmaceuticals Ltd leads gainers in 'B' group

SMS Lifesciences India Ltd, Hercules Hoists Ltd, Zuari Industries Ltd and Soma Textiles & ...

Read more

12 Mar 202412:15

News

SMS Pharmaceuticals to convene EGM

SMS Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company ...

Read more

14 Feb 202409:50

News

SMS Pharmaceuticals to hold board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 Febr...

Read more

05 Feb 202412:57

News

SMS Pharmaceuticals to discuss results

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 Nove...

Read more

04 Nov 202315:54

Product Composition by Percentage (Revenue)

FAQs for PE of SMS Pharmaceuticals Ltd

What is SMS Pharmaceuticals Ltd current share price?

The current market price of SMS Pharmaceuticals Ltd as of July 22, 2024 is ₹237.30.

What is SMS Pharmaceuticals Ltd's market cap?

SMS Pharmaceuticals Ltd's market capitalisation stood at ₹2,008 Cr as of July 22, 2024

What are SMS Pharmaceuticals Ltd's total net assets?

According to SMS Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹413.5 Cr.

Is SMS Pharmaceuticals Ltd making a profit or loss?

SMS Pharmaceuticals Ltd's net Profit as of July 22, 2024 is close to ₹49 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199